Piper Sandler Issues Positive Forecast for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its price target boosted by Piper Sandler from $24.00 to $27.00 in a research report report published on Monday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research firms have also recently weighed in on KVUE. Canaccord Genuity Group cut their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and cut their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Citigroup cut their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Finally, UBS Group dropped their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $23.08.

Kenvue Stock Up 0.0 %

KVUE opened at $23.33 on Monday. The business’s fifty day moving average is $21.33 and its two-hundred day moving average is $22.21. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market cap of $44.72 billion, a price-to-earnings ratio of 44.01, a PEG ratio of 2.62 and a beta of 1.45. Kenvue has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts anticipate that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.52%. Kenvue’s dividend payout ratio is presently 154.72%.

Institutional Investors Weigh In On Kenvue

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alerus Financial NA boosted its position in shares of Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after buying an additional 491 shares during the period. Kiley Juergens Wealth Management LLC boosted its position in shares of Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after buying an additional 500 shares during the period. Principle Wealth Partners LLC boosted its position in shares of Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after buying an additional 500 shares during the period. White Pine Capital LLC boosted its position in shares of Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock worth $1,165,000 after buying an additional 542 shares during the period. Finally, Deseret Mutual Benefit Administrators boosted its position in shares of Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock worth $54,000 after buying an additional 568 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.